Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Charles Schoch Sells 9,884 Shares

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Charles Schoch sold 9,884 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $6.47, for a total value of $63,949.48. Following the completion of the sale, the insider now owns 62,520 shares of the company’s stock, valued at $404,504.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Charles Schoch also recently made the following trade(s):

• On Thursday, July 11th, Charles Schoch sold 8,897 shares of Candel Therapeutics stock. The stock was sold at an average price of $5.97, for a total value of $53,115.09.

Candel Therapeutics Stock Performance

NASDAQ:CADL opened at $6.01 on Monday. The company has a market cap of $178.83 million, a price-to-earnings ratio of -4.70 and a beta of -0.95. Candel Therapeutics, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $14.30. The company has a debt-to-equity ratio of 1.66, a quick ratio of 2.00 and a current ratio of 2.00. The stock has a fifty day moving average price of $7.73 and a 200-day moving average price of $4.74.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.28) EPS for the quarter. As a group, equities analysts anticipate that Candel Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.